- Home
- SEPN vs CELC Comparison
SEPN vs CELC Comparison
Compare SEPN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- CELC
- Stock Information
- Founded
- SEPN 2022
- CELC 2011
- Country
- SEPN United States
- CELC United States
- Employees
- SEPN N/A
- CELC N/A
- Industry
- SEPN
- CELC Medical Specialities
- Sector
- SEPN
- CELC Health Care
- Exchange
- SEPN NYSE
- CELC Nasdaq
- Market Cap
- SEPN 311.6M
- CELC 327.3M
- IPO Year
- SEPN 2024
- CELC 2017
- Fundamental
- Price
- SEPN $9.25
- CELC $10.63
- Analyst Decision
- SEPN Buy
- CELC Strong Buy
- Analyst Count
- SEPN 4
- CELC 5
- Target Price
- SEPN $27.00
- CELC $30.80
- AVG Volume (30 Days)
- SEPN 2.6M
- CELC 152.9K
- Earning Date
- SEPN 05-15-2025
- CELC 05-14-2025
- Dividend Yield
- SEPN N/A
- CELC N/A
- EPS Growth
- SEPN N/A
- CELC N/A
- EPS
- SEPN N/A
- CELC N/A
- Revenue
- SEPN $977,000.00
- CELC N/A
- Revenue This Year
- SEPN N/A
- CELC N/A
- Revenue Next Year
- SEPN N/A
- CELC N/A
- P/E Ratio
- SEPN N/A
- CELC N/A
- Revenue Growth
- SEPN 108.76
- CELC N/A
- 52 Week Low
- SEPN $4.17
- CELC $7.58
- 52 Week High
- SEPN $28.99
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- CELC 51.32
- Support Level
- SEPN N/A
- CELC $10.26
- Resistance Level
- SEPN N/A
- CELC $10.88
- Average True Range (ATR)
- SEPN 0.00
- CELC 0.59
- MACD
- SEPN 0.00
- CELC -0.02
- Stochastic Oscillator
- SEPN 0.00
- CELC 58.33
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.